Trial
NCT04656275
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Non-cystic Fibrosis Bronchiectasis
Intervention
BI 1323495
Why stopped
Company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-27